Convergence Investment Partners, LLC Corcept Therapeutics Inc Transaction History

Convergence Investment Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	BUY	$24.82 - $32.88 $272,573 - $361,088	10,982 New	10,982 $357,000
Q3 2018 Nov 13, 2018	SELL	$12.27 - $15.65 $912,360 - $1.16 Million	-74,357 Closed	0 $0
Q2 2018 Aug 07, 2018	SELL	$15.3 - $19.69 $558,511 - $718,763	-36,504 Reduced 32.93%	74,357 $1.17 Million
Q1 2018 May 14, 2018	BUY	$14.59 - $25.5 $317,186 - $554,370	21,740 Added 24.39%	110,861 $1.82 Million
Q4 2017 Jan 16, 2018	SELL	$15.77 - $20.72 $480,685 - $631,566	-30,481 Reduced 25.49%	89,121 $1.61 Million
Q3 2017 Nov 13, 2017	BUY	$12.3 - $19.3 $1.47 Million - $2.31 Million	119,602	119,602 $2.31 Million

349

86.1M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.32B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Convergence Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Convergence Investment Partners, LLC with notifications on news.